Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $20.00.

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Guggenheim lifted their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th.

Hedge Funds Weigh In On Nanobiotix

Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP bought a new stake in Nanobiotix during the 4th quarter worth approximately $220,000. Optiver Holding B.V. bought a new stake in Nanobiotix during the 3rd quarter worth approximately $101,000. Finally, Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Price Performance

Shares of NBTX opened at $29.95 on Monday. The stock’s fifty day simple moving average is $27.23 and its 200-day simple moving average is $22.83. Nanobiotix has a 12-month low of $2.99 and a 12-month high of $41.89.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.